Related Experiment Video
Updated: Aug 30, 2025
Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice
Published on: February 10, 2023
A randomized controlled trial of an enhanced recovery after surgery protocol in patients undergoing laparoscopic
Pavlos Papasavas1, Richard L Seip2, Tara McLaughlin3
1Hartford Healthcare Surgical Weight Loss Center, Hartford Hospital, 80 Seymour Street, Hartford, CT, 06106, USA. pavlos.papasavas@hhchealth.org.
Background:
The purpose of this study was to evaluate the effect of an enhanced recovery after surgery (ERAS) protocol on opioid and anti-emetic use, length of stay and safety after laparoscopic sleeve gastrectomy (LSG).
Methods:
Patients who underwent LSG between March 2018 and January 2019 at our accredited, high-volume bariatric surgery center were randomized to either standard of care (SOC) or ERAS. ERAS included a pre- and post-surgical medication regimen designed to reduce postoperative nausea, vomiting and pain. Outcomes included post-operative symptom scores, opioid use, anti-emetic use, time to achieve readiness for discharge (RFD) and inpatient and 30-day adverse events, readmissions and emergency department visits.
Results:
The final analysis included 130 patients, (SOC 65; ERAS 65). Groups did not differ on demographics or comorbidities. Relative to SOC, fewer ERAS patients utilized opioids in the hospital ward (72.3% vs. 95.4%; p < .001), peak pain scores were significantly lower, and median time to achieve RFD was shorter (28.0 h vs. 44.4 h; p = 0.001). More ERAS patients were discharged on post-operative day 1 (38.5% vs. 15.4%; p < .05). The overall use of rescue anti-emetic medications was not different between groups. Rates of postoperative 30-day events, readmissions, and emergency department visits did not differ between groups.
Conclusion:
Relative to SOC, ERAS was associated with earlier discharge, lower pain scores, less frequent use of opioids and use in lower amounts after LSG with no differences in 30 day safety outcomes.
